Nucleic Acid Nanoparticles for Triggering RNA Interference
RNA interference (RNAi) is a naturally occurring cellular post-transcriptional gene regulation process that utilizes small double-stranded RNAs to trigger and guide gene silencing. By introducing synthetic RNA duplexes called small-interfering RNAs (siRNAs), we can harness the RNAi machinery for therapeutic gene control and the treatment of various diseases.
NCI researchers created RNA, RNA-DNA, or DNA-RNA hybrid nanocubes consisting of a DNA or RNA core (composed of six strands) with attached RNA or DNA hybrid duplexes. The nanocubes can induce the reassociation of the RNA duplexes, which can then be processed by the human recombinant DICER enzyme, thus activating RNAi. This technology opens a new route for the development of “smart” nucleic acid based nanoparticles for a wide range of biomedical applications. Immune responses can be controlled by altering the composition of the particle.
The researchers are conducting preliminary mouse xenograft studies on a related potential therapeutic, and seek collaborators for scale-up, animal models, developing particles for multiple targets, and RNAi delivery methods.
Competitive Advantages:
• Low cytotoxicity
Commercial Applications:
• Treatment for cancer and infectious diseases.
Related Inventions
-
E-039-2012
TAB-4169
Nanoparticles for the targeted treatment of infected cells -
E-078-2016
TAB-3873
RNA/DNA Nanoparticles as Cancer Therapeutics -
E-765-2013
TAB-4077
Multifunctional RNA Nanoparticles as Cancer and HIV Therapeutics
Patents
- US
Provisional (PRV) 61/989,520
Filed on 2014-05-06
Status: Abandoned - Patent Cooperation Treaty
(PCT) PCT/US2015/029553
Filed on 2015-05-06
Status: Expired - US Patent 10,517,890
Filed on 2016-11-04
Status: Issued - US
Provisional (PRV) 61/990,094
Filed on 2014-05-07
Status: Abandoned - US
Continuation in Part (CIP) 16/717,060
Filed on 2019-12-17
Status: Abandoned
Publications
Collaborations
- Licensing
- Collaboration